GG13
GG13 is an anti-inflammatory peptide. GG13 reduces the expression of STAT1, NOS2, COX2, and CD40. GG13 decreases the expression and secretion of iNOS and TNF-α proteins. GG13 is applicable to the research of inflammatory diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C48H76N16O17
- Masse moléculaire:1149.21
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
Description
IC50 & Target
[1]|
COX-2 |
STAT1 |
iNOS |
NOS2 |
In Vitro
GG13 (25-400 μg/mL; 20 h) promotes the proliferation of RAW264.7 macrophages without reducing cell viability[1].
GG13 (50-400 μg/mL; 12 h) inhibits LPS-stimulated NO production in RAW264.7 macrophages in a concentration-dependent manner, with an inhibition rate of 68.81% at 200 μg/mL and 73.53% at 400 μg/mL[1].
GG13 downregulates the expression of key pro-inflammatory proteins STAT1, NOS2, COX2 and CD40 in LPS-stimulated RAW264.7 macrophages, a finding confirmed by label-free proteomic analysis[1].
GG13 (50-200 μg/mL; 12 h) inhibits TNF-α secretion in LPS-stimulated RAW264.7 macrophages in a concentration-dependent manner, with an inhibition rate of 40.25% at the concentration of 200 μg/mL[1].
GG13 (50-200 μg/mL; 12 h) reduces the expression of pro-inflammatory iNOS and TNF-α proteins in LPS-stimulated RAW264.7 macrophages in a concentration-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 macrophages
-
Concentration:25-400 μg/mL
-
Incubation Time:20 h
-
Result:Enhanced cell proliferation across all tested concentrations without significantly affecting cell viability, relative to untreated control cells.
-
Cell Line:LPS-stimulated RAW264.7 macrophages
-
Concentration:50-200 μg/mL
-
Incubation Time:12 h pre-incubation, followed by 8 h LPS co-incubation
-
Result:Inhibited TNF-α secretion in a concentration-dependent manner (p < 0.001).
Reduced TNF-α secretion by 40.25% at 200 μg/mL.
-
Cell Line:LPS-stimulated RAW264.7 macrophages
-
Concentration:50-200 μg/mL
-
Incubation Time:12 h pre-incubation, followed by 8 h LPS co-incubation
-
Result:Reduced the expression of iNOS and TNF-α proteins significantly in a concentration-dependent manner (p < 0.01).
Chemical Information
-
Masse moléculaire 1149.21
-
Formule C48H76N16O17
-
Sequence
Gly-Pro-Gly-Ala-Pro-Ala-Asp-Pro-Gly-Arg-Pro-Thr-Gly
-
Sequence Shortening
GPGAPADPGRPTG
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)